SINGLE DOSE AND STEADY-STATE PHARMACOKINETIC PROFILES OF NIFEDIPINE GITS TABLETS IN HEALTHY ELDERLY AND YOUNG VOLUNTEERS

被引：11

作者：

CROME, P ^{[1
]}

MULLER, FO ^{[1
]}

WIJAYAWARDHANA, P ^{[1
]}

GROENEWOUD, G ^{[1
]}

HUNDT, HKL ^{[1
]}

LEIGHTON, G ^{[1
]}

LUUS, HG ^{[1
]}

SCHALL, R ^{[1
]}

VANDYK, M ^{[1
]}

机构：

[1] ORPINGTON HOSP,DEPT HLTH CARE ELDERLY,ORPINGTON,KENT,ENGLAND

来源：

DRUG INVESTIGATION | 1993年 / 5卷 / 04期

关键词：

D O I：

10.1007/BF03258446

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The pharmacokinetics of a once-daily extended-release nifedipine formulation [Gastro-Intestinal Therapeutic System (GITS)] was studied in 23 young males and 24 elderly male and female volunteers, after single and multiple dosing of 60mg nifedipine GITS tablets once daily for 7 days, in an open nonrandomised study. Serial blood samples for plasma nifedipine levels were drawn on days 1 and 7, and the pharmacokinetic profiles of the elderly and young volunteers were compared after both single and multiple dosing. After a single dose the plasma nifedipine concentrations in the young and elderly were similar. but at steady-state after multiple dosing the plasma concentrations were slightly higher in the elderly than in the young volunteers. Nifedipine GITS displayed distinct extended-release properties, and it appears that dose reduction will not be required for otherwise healthy elderly subjects.

引用

页码：193 / 199

页数：7

共 16 条

[1]

Avgerinos A., Gorrod J.W., Pharmacokinetics of nifedipine derived from a new retard tablet formulation, European Journal of Drug Metabolism and Pharmacokinetics, 15, pp. 273-278, (1990)

[2]

Bittar N., Usefulness of nifedipine for myocardial ischaemia and the nifedipine gastrointestinal therapeutic system, American Journal of Cardiology, 64, pp. 31F-34F, (1989)

[3]

Bravo E.L., Krakoff L.R., Tuck N.L., Friedman C.P., Antihypertensive effectiveness of nifedipine gastrointestinal therapeutic system in the elderly, American Journal of Hypertension, 3, pp. 326S-332S, (1990)

[4]

Chung M., Reitberg D.P., Gaffney M., Singleton W., Clinical pharmacokinetics of nifedipine gastrointestinal therapeutic system. A controlled-release formulation, American Journal of Medicine, 83, pp. 10-14, (1987)

[5]

Debbas N.M.G., Jackson S.H.D., Shah K., Abra S.M.L., Johnston A., Et al., The bioavailability and pharmacokinetics of slow-release nifedipine during chronic dosing in volunteers, British Journal of Clinical Pharmacology, 21, pp. 385-388, (1986)

[6]

Kohri N., Miyazaki K., Arita T., Shimono H., Nomura A., Et al., Release characteristics of nifedipine sustained-release granules in vitro and in healthy subjects, Chemical and Pharmaceutical Bulletin, 35, pp. 2504-2509, (1987)

[7]

Leucuta S.E., The kinetics of nifedipine release from porous hydrophilic matrices and the pharmacokinetics in man, Pharmazie, 43, pp. 845-848, (1988)

[8]

Murdoch D., Brogden R.N., Sustained release nifedipine formulations. An appraisal of their current uses and prospective roles in the treatment of hypertension, ischaemic heart disease and peripheral vascular disorders, Drugs, 41, pp. 737-779, (1991)

[9]

Ohnishi N., Yokoyama T., Umeda T., Kiyohara Y., Kuroda T., Et al., Application of nifedipine sustained-release suppositories to healthy volunteers, Chemical and Pharmaceutical Bulletin, 35, pp. 1294-1298, (1987)

[10]

Robertson D.R.C., Waller D.G., Renwick A.G., George C.F., Age-related changes in the pharmacokinetics and pharmacodynamics of nifedipine, British Journal of Clinical Pharmacology, 25, pp. 297-305, (1988)

← 1 2 →